NCT06567795View on ClinicalTrials.gov

PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

RecruitingOBSERVATIONAL
Enrollment

189

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

March 18, 2026

Study Completion Date

March 18, 2027

Conditions
Diabetes Mellitus Type 2Cardiovascular DiseasesCoronary Artery DiseaseCerebrovascular DiseasePeripheral Artery Disease
Interventions
DEVICE

Hemotag

Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days

Trial Locations (1)

33401'

RECRUITING

Metabolic Research Institute, Inc, West Palm Beach

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Aventusoft, LLC.

INDUSTRY